English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 855610 Online Users : 1257
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by
NTU Library IR team.
Scope
All of NHRI
National Institute of Cancer Research
Li-Tzong Chen
--Periodical Articles
Tips:
please add "double quotation mark" for query phrases to get precise results
please goto advance search for comprehansive author search
Adv. Search
Home
‧
Login
‧
Upload
‧
Help
‧
About
‧
Administer
NHRI
>
National Institute of Cancer Research
>
Li-Tzong Chen
>
Periodical Articles
>
Browse By Title
Browse By Authors
Browse By Date
Browse By Data Type
Loading...
Siblings
Books/Book Section
[
1
/1]
Conference Papers/Meeting Abstract
[
115
/179]
Collection Statistics
Item counts issued in 3 years:58(17.58%)
Items With Fulltext:327(99.09%)
Download counts of the item
Download times greater than 0:327(100.00%)
Download times greater than 100:311(95.11%)
Total Bitstream Download Counts:137583(77.78%)
Last Update: 2024-11-28 10:18
Top Upload
Loading...
Top Download
Loading...
Recent Submissions
Pan-Asian adapted ESMO clinical pra...
Nivolumab plus chemotherapy in pati...
Survival of advanced/recurrent gast...
Topiramate suppresses peri-infarct ...
A phase 1 study of biweekly nab-pac...
Plain language summary of the FOENI...
Outcomes of post-immunotherapy dura...
Durvalumab or placebo plus gemcitab...
Impact of previous S-1 treatment on...
Chromatin remodeling-related PRDM1 ...
Jump to a point in the index:
(Choose year)
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1985
1980
1975
1970
1960
1950
(Choose month)
January
February
March
April
May
June
July
August
September
October
November
December
Or type in a year:
Ordering With Most Recent First
Show Oldest First
Showing items 1-25 of 330. (14 Page(s) Totally)
1
2
3
4
5
6
7
8
9
10
>
>>
View [
10
|
25
|
50
] records per page
Date
Title
Relation
2024-10
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
Oncologist. 2024 Oct 3;29(10):e1396-e1405.
2024-08-20
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
Gastric Cancer. 2024 Aug 20;Article in Press.
2024-08-06
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer
ESMO Open. 2024 Aug 06;9(8):Article number 103647.
2024-08
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study
Lancet. Gastroenterology and Hepatology. 2024 Aug;9(8):694-704.
2024-07-11
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study
BMC Cancer. 2024 Jul 11;24:Article number 828.
2024-06-21
Topiramate suppresses peri-infarct spreading depolarization and improves outcomes in a rat model of photothrombotic stroke
iScience. 2024 Jun 21;27(6):Article number 110033.
2024-06-17
Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer
Future Oncology. 2024 Jun 17;Article in Press.
2024-05
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
Pancreatology. 2024 May;24(3):600-607.
2024-03
RNF43 inactivation enhances the B-RAF/MEK signaling and greates a combinatory therapeutic target in cancer cells
Advanced Science. 2024 Mar;11(12):Article number e2304820.
2024-02-20
Chromatin remodeling-related PRDM1 increases stomach cancer proliferation and is counteracted by bromodomain inhibitor
Journal of Personalized Medicine. 2024 Feb 20;14(3):Article number 224.
2024-02-15
Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway
American Journal of Cancer Research. 2024 Feb 15;14(2):448-466.
2024-02-13
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan
Journal of Biomedical Science. 2024 Feb 13;31:Article number 21.
2024-02-01
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression
Liver Cancer. 2024 Feb 01;Article in Press.
2023-11-22
The prognosis performance of a neutrophil- and lymphocyte-associated gene mutation score in a head and neck cancer cohort
Biomedicines. 2023 Nov 22;11(12):Article number 120209.
2023-11
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
Future Oncology. 2023 Nov;19(34):2277-2289.
2023-10
The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: A noninterventional, uncontrolled multicenter study
British Journal of Cancer. 2023 Oct;129(6):947-955.
2023-09-01
The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study
International Journal of Surgery. 2023 Sep 1;109(9):2614-2623.
2023-09
Carbohydrate antigen 19-9 response to initial adjuvant chemotherapy predicts survival and failure pattern of resected pancreatic adenocarcinoma but not which patients are suited for additional adjuvant chemoradiation therapy: From a prospective randomized study
International Journal of Radiation Oncology Biology Physics. 2023 Sep 1;117(1):74-86.
2023-08-15
Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination
American Journal of Cancer Research. 2023 Aug 15;13(8):3417-3432.
2023-08
The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study
Cancer Medicine. 2023 Aug;12(16):16906-16917.
2023-07
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462
Annals of Oncology. 2023 Jul;34(7):633.
2023-05-24
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer
ESMO Open. 2023 May 24;8(3):Article number 101558.
2023-05-01
The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy
Experimental and Molecular Medicine. 2023 May;55(5):926-938.
2023-02-24
Deciphering the functions of telomerase reverse transcriptase in head and neck cancer
Biomedicines. 2023 Feb 24;11(3):Article number 691.
2023-02-05
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
Cancers. 2023 Feb 5;15(4):Article number 1008.
Showing items 1-25 of 330. (14 Page(s) Totally)
1
2
3
4
5
6
7
8
9
10
>
>>
View [
10
|
25
|
50
] records per page
DSpace Software
Copyright © 2002-2004
MIT
&
Hewlett-Packard
/
Enhanced by
NTU Library IR team
Copyright ©
-
Feedback